Modalities beyond small molecules

Design and synthesis of degraders, ADCs and peptide libraries

Nuvisan offers a comprehensive suite of chemistry services across various advanced therapeutic modalities:

Proteolysis targeting chimeras (PROTAC^®s)

• Optimisation of exit vectors, linker length and composition for oral bioavailability.
• Digital Life Sciences support, including:
  • Binder design for POIs/E3 ligases
  • Structure-based and de novo linker optimisation
  • Ternary complex prediction
• Proven track record in delivering preclinical PROTAC^® compounds efficiently.

Antibody–drug conjugates (ADCs)

•  Advanced linker optimisation to reduce systemic exposure and limit toxicity.

Peptide-based drug development

• Parallel peptide synthesis in 48/96-well reactors for sequences up to 20 amino acids
• Design and incorporation of non-natural amino acids
• Specialised expertise in:
  • Peptide stapling and cyclic peptide design.
  • 18F-labelling for advanced applications.
  • SAR generation and PK optimisation for peptide-based small molecules.

These capabilities allow Nuvisan to deliver precise and innovative solutions, driving progress in your drug discovery programs.